1. Home
  2. CHRS
  3. CHRS News

Latest Coherus BioSciences Inc. (CHRS) News on November 21, 2024

CHRS

Thomson Reuters StreetEvents

14 days ago

Q3 2024 Coherus BioSciences Inc Earnings Call

Coherus BioSciences Inc (CHRS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...
CHRS

GuruFocus.com

14 days ago

Coherus BioSciences Inc (CHRS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...

Coherus BioSciences (CHRS) Reports Q3 Loss, Tops Revenue Estimates
CHRS

Zacks

15 days ago

Coherus BioSciences (CHRS) Reports Q3 Loss, Tops Revenue Estimates

CHRS

Associated Press Finance

15 days ago

Coherus BioSciences: Q3 Earnings Snapshot

Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update
CHRS

GlobeNewswire

15 days ago

Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Coherus BioSciences Inc (CHRS) Q3 2024: Everything You Need to Know Ahead of Earnings
CHRS

GuruFocus.com

16 days ago

Coherus BioSciences Inc (CHRS) Q3 2024: Everything You Need to Know Ahead of Earnings

Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024
CHRS

GlobeNewswire

22 days ago

Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024

Coherus BioSciences Inc (CHRS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ...
CHRS

GuruFocus.com

a month ago

Coherus BioSciences Inc (CHRS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ...

Coherus BioSciences, Inc. (CHRS): Worst 52-Week Low Stock to Buy Now
CHRS

Insider Monkey

2 months ago

Coherus BioSciences, Inc. (CHRS): Worst 52-Week Low Stock to Buy Now

Short Interest Surges to 21.83% as Coherus BioSciences, Inc. (CHRS) Faces Revenue Challenges
CHRS

Insider Monkey

2 months ago

Short Interest Surges to 21.83% as Coherus BioSciences, Inc. (CHRS) Faces Revenue Challenges

Institutional owners may take dramatic actions as Coherus BioSciences, Inc.'s (NASDAQ:CHRS) recent 12% drop adds to one-year losses
CHRS

Simply Wall St.

2 months ago

Institutional owners may take dramatic actions as Coherus BioSciences, Inc.'s (NASDAQ:CHRS) recent 12% drop adds to one-year losses

CHRS

MT Newswires

3 months ago

Coherus BioSciences Shares Decline After Downgrade From UBS

CHRS

MT Newswires

3 months ago

UBS Downgrades Coherus BioSciences to Neutral From Buy, Adjusts Price Target to $1.50 From $4

Coherus BioSciences Second Quarter 2024 Earnings: Beats Expectations
CHRS

Simply Wall St.

3 months ago

Coherus BioSciences Second Quarter 2024 Earnings: Beats Expectations

Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates
CHRS

Zacks

3 months ago

Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates

CHRS

Associated Press Finance

3 months ago

Coherus BioSciences: Q2 Earnings Snapshot

Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update
CHRS

GlobeNewswire

3 months ago

Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update

Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024
CHRS

GlobeNewswire

4 months ago

Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024

CHRS

MT Newswires

5 months ago

Coherus BioSciences Grants Apotex License to Distribute Toripalimab in Canada

CHRS

MT Newswires

5 months ago

Baird Trims Price Target on Coherus BioSciences to $8 From $9, Maintains Outperform Rating

PTC faces another Duchenne drug rejection; Coherus sells Humira biosimilar
CHRS

BioPharma Dive

5 months ago

PTC faces another Duchenne drug rejection; Coherus sells Humira biosimilar

CHRS

MT Newswires

5 months ago

Coherus BioSciences to Sell Yusimry to Hong Kong King-Friend Industrial in $40 Million Cash Transaction

Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction
CHRS

GlobeNewswire

5 months ago

Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction

Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition
CHRS

Business Wire

5 months ago

Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition

Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus
CHRS

GlobeNewswire

5 months ago

Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus

Share buy-back programme - week 23
CHRS

GlobeNewswire

5 months ago

Share buy-back programme - week 23

Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?
CHRS

Simply Wall St.

5 months ago

Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?

Japan's service sector mood hits nearly 2-year low in May
CHRS

Reuters

5 months ago

Japan's service sector mood hits nearly 2-year low in May

N. Korea sends more balloons as Kim's sister warns of 'new counteraction'
CHRS

AFP

5 months ago

N. Korea sends more balloons as Kim's sister warns of 'new counteraction'

Velcan Holdings: buyback offer of 500 000 shares at Eur 14.5 per share
CHRS

GlobeNewswire

5 months ago

Velcan Holdings: buyback offer of 500 000 shares at Eur 14.5 per share

Enduring role of 'treasuring the past' hailed
CHRS

PR Newswire

5 months ago

Enduring role of 'treasuring the past' hailed

Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors
CHRS

GlobeNewswire

6 months ago

Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors

Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference
CHRS

GlobeNewswire

6 months ago

Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference

Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
CHRS

GlobeNewswire

6 months ago

Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA
CHRS

GlobeNewswire

6 months ago

Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA

We Think Some Shareholders May Hesitate To Increase Coherus BioSciences, Inc.'s (NASDAQ:CHRS) CEO Compensation
CHRS

Simply Wall St.

6 months ago

We Think Some Shareholders May Hesitate To Increase Coherus BioSciences, Inc.'s (NASDAQ:CHRS) CEO Compensation

CHRS

MT Newswires

6 months ago

Truist Securities Trims Price Target on Coherus BioSciences to $7 From $8, Maintains Buy Rating

Coherus BioSciences First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
CHRS

Simply Wall St.

6 months ago

Coherus BioSciences First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Coherus BioSciences, Inc. (NASDAQ:CHRS) Q1 2024 Earnings Call Transcript
CHRS

Insider Monkey

6 months ago

Coherus BioSciences, Inc. (NASDAQ:CHRS) Q1 2024 Earnings Call Transcript

Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates
CHRS

Zacks

6 months ago

Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates

CHRS

Associated Press Finance

6 months ago

Coherus BioSciences: Q1 Earnings Snapshot

Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
CHRS

GlobeNewswire

6 months ago

Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update

Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan
CHRS

GlobeNewswire

6 months ago

Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan

When Can We Expect A Profit From Coherus BioSciences, Inc. (NASDAQ:CHRS)?
CHRS

Simply Wall St.

6 months ago

When Can We Expect A Profit From Coherus BioSciences, Inc. (NASDAQ:CHRS)?

Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer
CHRS

GlobeNewswire

6 months ago

Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer

Coherus to Report First Quarter 2024 Financial Results on May 9, 2024
CHRS

GlobeNewswire

7 months ago

Coherus to Report First Quarter 2024 Financial Results on May 9, 2024

Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
CHRS

GlobeNewswire

7 months ago

Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Investors in Coherus BioSciences (NASDAQ:CHRS) have unfortunately lost 83% over the last five years
CHRS

Simply Wall St.

7 months ago

Investors in Coherus BioSciences (NASDAQ:CHRS) have unfortunately lost 83% over the last five years

Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting
CHRS

GlobeNewswire

7 months ago

Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting

Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2023 Earnings Call Transcript
CHRS

Insider Monkey

8 months ago

Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2023 Earnings Call Transcript

Coherus BioSciences Full Year 2023 Earnings: EPS Misses Expectations
CHRS

Simply Wall St.

8 months ago

Coherus BioSciences Full Year 2023 Earnings: EPS Misses Expectations

Why Coherus Biosciences Stock Tumbled on Thursday
CHRS

Motley Fool

8 months ago

Why Coherus Biosciences Stock Tumbled on Thursday

CHRS

Thomson Reuters StreetEvents

8 months ago

Q4 2023 Coherus BioSciences Inc Earnings Call

Coherus BioSciences Inc (CHRS) Reports Growth in Net Revenue for Q4 and Full Year 2023 Despite ...
CHRS

GuruFocus.com

8 months ago

Coherus BioSciences Inc (CHRS) Reports Growth in Net Revenue for Q4 and Full Year 2023 Despite ...

CHRS

Associated Press Finance

8 months ago

Coherus BioSciences: Q4 Earnings Snapshot

Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
CHRS

GlobeNewswire

8 months ago

Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update

In the wake of Coherus BioSciences, Inc.'s (NASDAQ:CHRS) latest US$49m market cap drop, institutional owners may be forced to take severe actions
CHRS

Simply Wall St.

9 months ago

In the wake of Coherus BioSciences, Inc.'s (NASDAQ:CHRS) latest US$49m market cap drop, institutional owners may be forced to take severe actions

Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024
CHRS

GlobeNewswire

9 months ago

Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024

Coherus Completes Divestiture of Ophthalmology Franchise
CHRS

GlobeNewswire

9 months ago

Coherus Completes Divestiture of Ophthalmology Franchise

Coherus BioSciences Announces New Employment Inducement Grants
CHRS

GlobeNewswire

9 months ago

Coherus BioSciences Announces New Employment Inducement Grants

Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
CHRS

GlobeNewswire

9 months ago

Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

Why Coherus BioSciences Stock Jumped Today
CHRS

Motley Fool

9 months ago

Why Coherus BioSciences Stock Jumped Today

Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP
CHRS

GlobeNewswire

10 months ago

Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP

Coach says Japan must improve in 'many aspects' after Asian Cup exit
CHRS

AFP

10 months ago

Coach says Japan must improve in 'many aspects' after Asian Cup exit

WaFd (WAFD)-Luther Burbank (LBC) Merger Gets Regulatory Nod
CHRS

Zacks

10 months ago

WaFd (WAFD)-Luther Burbank (LBC) Merger Gets Regulatory Nod

Invesco Closed-End Funds Declare Dividends
CHRS

PR Newswire

10 months ago

Invesco Closed-End Funds Declare Dividends

When Can We Expect A Profit From Youdao, Inc. (NYSE:DAO)?
CHRS

Simply Wall St.

10 months ago

When Can We Expect A Profit From Youdao, Inc. (NYSE:DAO)?

First Community Bankshares (NASDAQ:FCBC) Is Due To Pay A Dividend Of $0.29
CHRS

Simply Wall St.

10 months ago

First Community Bankshares (NASDAQ:FCBC) Is Due To Pay A Dividend Of $0.29

Univest Financial Full Year 2023 Earnings: EPS Beats Expectations
CHRS

Simply Wall St.

10 months ago

Univest Financial Full Year 2023 Earnings: EPS Beats Expectations

Peapack-Gladstone (PGC) Misses Q4 Earnings and Revenue Estimates
CHRS

Zacks

10 months ago

Peapack-Gladstone (PGC) Misses Q4 Earnings and Revenue Estimates

ACNB Corp (ACNB) Reports Decline in Q4 Net Income Amid Investment Portfolio Repositioning
CHRS

GuruFocus.com

10 months ago

ACNB Corp (ACNB) Reports Decline in Q4 Net Income Amid Investment Portfolio Repositioning

Analysts Are More Bearish On Coherus BioSciences, Inc. (NASDAQ:CHRS) Than They Used To Be
CHRS

Simply Wall St.

10 months ago

Analysts Are More Bearish On Coherus BioSciences, Inc. (NASDAQ:CHRS) Than They Used To Be

Atrion (NASDAQ:ATRI) investors are sitting on a loss of 54% if they invested five years ago
CHRS

Simply Wall St.

10 months ago

Atrion (NASDAQ:ATRI) investors are sitting on a loss of 54% if they invested five years ago

Why Coherus BioSciences Stock Is Sinking Today
CHRS

Motley Fool

10 months ago

Why Coherus BioSciences Stock Is Sinking Today

Why Coherus Biosciences Popped Today
CHRS

Motley Fool

10 months ago

Why Coherus Biosciences Popped Today

CVRx (CVRX) Upgraded to Strong Buy: What Does It Mean for the Stock?
CHRS

Zacks

10 months ago

CVRx (CVRX) Upgraded to Strong Buy: What Does It Mean for the Stock?

Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal
CHRS

GlobeNewswire

10 months ago

Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal

Is First Business Financial Services (FBIZ) Stock Undervalued Right Now?
CHRS

Zacks

10 months ago

Is First Business Financial Services (FBIZ) Stock Undervalued Right Now?

Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium
CHRS

GlobeNewswire

10 months ago

Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium

Applied Digital Reports Fiscal Second Quarter 2024 Results
CHRS

GlobeNewswire

10 months ago

Applied Digital Reports Fiscal Second Quarter 2024 Results

Houthis Turn Their Sights on U.S. Ships, Vow to Keep Attacking Red Sea Targets
CHRS

The Wall Street Journal

10 months ago

Houthis Turn Their Sights on U.S. Ships, Vow to Keep Attacking Red Sea Targets

Invesco Municipal Trust's Dividend Analysis
CHRS

GuruFocus.com

10 months ago

Invesco Municipal Trust's Dividend Analysis

Here’s Why Aristotle Small Cap Equity Strategy Sold Coherus BioSciences (CHRS)
CHRS

Insider Monkey

10 months ago

Here’s Why Aristotle Small Cap Equity Strategy Sold Coherus BioSciences (CHRS)

Gatos Silver Reports 2023 Silver Production Near Top End of Guidance
CHRS

GlobeNewswire

10 months ago

Gatos Silver Reports 2023 Silver Production Near Top End of Guidance

Progyny, Inc. to Present at 42nd Annual J.P. Morgan Healthcare Conference
CHRS

GlobeNewswire

10 months ago

Progyny, Inc. to Present at 42nd Annual J.P. Morgan Healthcare Conference

Guaranty Bancshares, Inc. Announces Fourth Quarter and Year-End 2023 Earnings Release and Conference Call Schedule
CHRS

Business Wire

a year ago

Guaranty Bancshares, Inc. Announces Fourth Quarter and Year-End 2023 Earnings Release and Conference Call Schedule

INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi)
CHRS

PR Newswire

a year ago

INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi)

Maui Land & Pineapple Company appoints new board members to support next chapter of growth
CHRS

GlobeNewswire

a year ago

Maui Land & Pineapple Company appoints new board members to support next chapter of growth

Coherus BioSciences Management to Present at the 42nd Annual J.P. Morgan Healthcare Conference
CHRS

GlobeNewswire

a year ago

Coherus BioSciences Management to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Melt Pharmaceuticals Provides Corporate Update
CHRS

Business Wire

a year ago

Melt Pharmaceuticals Provides Corporate Update

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) is definitely on the radar of institutional investors who own 40% of the company
CHRS

Simply Wall St.

a year ago

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) is definitely on the radar of institutional investors who own 40% of the company

Coherus (CHRS) Stock Rallies on FDA Nod for Udenyca Onbody
CHRS

Zacks

a year ago

Coherus (CHRS) Stock Rallies on FDA Nod for Udenyca Onbody

CHRS

Reuters

a year ago

Dazheng Group consortium announces bid to buy Hollysys Automation for $1.8 billion

CHRS

Reuters

a year ago

Dazheng Group consortium announces bid to buy Hollysys Automation at $1.8 bln

Donegal Group Inc. Announces Quarterly Dividend
CHRS

GlobeNewswire

a year ago

Donegal Group Inc. Announces Quarterly Dividend

Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 42nd Annual Healthcare Conference
CHRS

PR Newswire

a year ago

Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 42nd Annual Healthcare Conference

Northeast Bank (NASDAQ:NBN) is favoured by institutional owners who hold 60% of the company
CHRS

Simply Wall St.

a year ago

Northeast Bank (NASDAQ:NBN) is favoured by institutional owners who hold 60% of the company

CHRS

Investing.com

a year ago

Macy's shares jump 20% on $5.8 billion buyout offer: 4 big deal reports

Red River Bancshares, Inc. Announces Renewal of Stock Repurchase Program
CHRS

GlobeNewswire

a year ago

Red River Bancshares, Inc. Announces Renewal of Stock Repurchase Program

10 Very Cheap Energy Stocks Ready To Explode
CHRS

Insider Monkey

a year ago

10 Very Cheap Energy Stocks Ready To Explode

Share on Social Networks: